In mouse models, inhibiting prostaglandin G/H synthase 2 (COX2) or using PGE2 receptor EP1/EP2 antagonists can redirect anti-tumor effectors and improve the effectiveness of ICB [190]. This evidence concerns the gene PTGS2 and neoplasm.